Telenzepine

Telenzepine

SCHEMBL2006403

Cc1scc2c1N(C(=O)CN1CCN(C)CC1)c1ccccc1NC2=O.N

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 3/20 0.98
ALDH1A1 P00352 2/20 0.98
CYP1A2 P05177 2/20 0.98
CYP3A4 P08684 2/20 0.98
CYP2C9 P11712 1/20 0.98
TSHR P16473 1/20 0.98
CYP2C19 P33261 1/20 0.98
L3MBTL1 Q9Y468 1/20 0.98
LMNA P02545 3/20 0.96
CHRM1 P11229 4/20 0.56
CHRM2 P08172 3/20 0.56
CHRM4 P08173 2/20 0.56
CHRM3 P20309 2/20 0.56
USP2 O75604 1/20 0.56
CHRM5 P08912 1/20 0.56
GMNN O75496 1/20 0.55
APEX1 P27695 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Telenzepine SCHEMBL49345 0.99 CYP2D6 (1.00) CYP2D6ALDH1A1CYP1A2CYP3A4CYP2C9
Telenzepine SCHEMBL184401 0.98 LMNA (1.00) CYP2D6ALDH1A1CYP1A2CYP3A4CYP2C9
Telenzepine SCHEMBL970991 0.98 LMNA (1.00) CYP2D6ALDH1A1CYP1A2CYP3A4CYP2C9
Telenzepine SCHEMBL14973496 0.97 ALDH1A1 (0.96) CYP2D6ALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL11192698 0.91 ALDH1A1 (0.85) CYP2D6ALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL9431778 0.89 ALDH1A1 (0.82) CYP2D6ALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL9727995 0.89 ALDH1A1 (0.81) CYP2D6ALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL11187135 0.88 CYP2D6 (0.80) CYP2D6ALDH1A1CYP1A2CYP3A4CYP2C9
Pirenzepine SCHEMBL935909 0.88 ALDH1A1 (0.79) CYP2D6ALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL9431091 0.87 ALDH1A1 (0.78) CYP2D6ALDH1A1CYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964361-B2 Rigidized trimethine cyanine dyes CARNEGIE MELLON UNIVERSITY (US) 2011-06-21 US disclosed
US-20090281279-A1 Rigidized trimethine cyanine dyes CARNEGIE MELLON UNIVERSITY (US) 2009-11-12 US disclosed
US-7408062-B2 Rigidized trimethine cyanine dyes CARNEGIE MELLON UNIVERSITY (US) 2008-08-05 US disclosed
US-20070243527-A9 RIGIDIZED TRIMETHINE CYANINE DYES CARNEGIE MELLON UNIVERSITY 2007-10-18 US disclosed
US-6686145-B1 IMPARTING FLUORESCENT PROPERTIES TO TARGET MATERIALS BY COVALENT AND NONCOVALENT ASSOCIATION CARNEGIE MELLON UNIVERSITY 2004-02-03 US disclosed
US-20030224391-A1 Rigidized trimethine cyanine dyes CARNEGIE MELLON UNIVERSITY 2003-12-04 US disclosed
EP-1042407-B1 RIGIDIZED TRIMETHINE CYANINE DYES UNIV CARNEGIE MELLON (US) 2001-09-12 EP disclosed
US-6133445-A USEFUL FOR IMPARTING FLUORESCENT PROPERTIES TO TARGET MATERIALS CARNEGIE MELLON UNIVERSITY (US) 2000-10-17 US disclosed
EP-1042407-A1 RIGIDIZED TRIMETHINE CYANINE DYES CARNEGIE-MELLON UNIVERSITY (US) 2000-10-11 EP disclosed
WO-1999031181-A1 RIGIDIZED TRIMETHINE CYANINE DYES CARNEGIE MELLON UNIVERSITY (US) 1999-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070243527-A9 RIGIDIZED TRIMETHINE CYANINE DYES SIGMAR1, CBR1, NR0B1 CYP2D6 566/4885ALDH1A1 1428/4885CYP1A2 272/4885
US-20090281279-A1 Rigidized trimethine cyanine dyes CD47, TLN1, TPM4 CYP2D6 4003/4885ALDH1A1 3193/4885CYP1A2 3515/4885
US-20030224391-A1 Rigidized trimethine cyanine dyes CBR1, TH, CBR3 CYP2D6 1565/4885ALDH1A1 2154/4885CYP1A2 1370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.